Saturday, July 2, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Cross-species infectivity of SARS-CoV-2 variants correlated with prevalence

by Medical Finance
in Coronavirus
Study: Cross-species tropism and antigenic landscapes of circulating SARS-CoV-2 variants. Image Credit: Lightspring/Shutterstock
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to the coronavirus disease 2019 (COVID-19) pandemic. Despite the rapid rollout of vaccines, the emergence of newer variants of the virus, some with higher transmissibility and others with immune escape capabilities, led to the continuation of the viral spread.

Study: Cross-species tropism and antigenic landscapes of circulating SARS-CoV-2 variants. Image Credit: Lightspring/Shutterstock
Study: Cross-species tropism and antigenic landscapes of circulating SARS-CoV-2 variants. Image Credit: Lightspring/Shutterstock

A new paper in the journal Cell Reports discusses the role of mutations in the receptor-binding domain (RBD) of the spike protein in the generation of antibody resistance and loss of vaccine efficacy.

Introduction

Given the many variants that have been identified so far, the need to study the antigenic landscape in relation to the tropism of the virus, and other biological effects, is obvious. The current study focused on the numerous RBD variants deposited in the public SARS-CoV-2 genome database, 129 in all, along with 24 double-mutant RBDs, and 11 variants of the virus, either variants of concern or variants of interest (VOC/VOI), respectively.

These were expressed in lentiviral-pseudotyped particles (LVpp), and their infectivity potential measured against cells expressing heterologous angiotensin converting enzyme 2 (ACE2) receptors from 18 animal species. The ability to neutralize these various particles was measured, using human convalescent plasma samples (HCP), and polyclonal antibodies from vaccine or vaccine-candidate-derived sera, and monoclonal antibodies (mAbs).

The scientists also tracked the correlation between the mutations in the circulating RBD variants and the potential for cross-species infection and antibody escape.

What did the study show?

The results showed that of the 129 RBD mutants, 17 showed a reduction in spike expression by over 50%, compared to the wildtype D614G strain, while ~5% had significantly reduced spike expression. This translated to >5-fold loss of infectivity to the wildtype variant, while others showed a slight increase.

The SARS-CoV-2 spike bound efficiently to 13 of 18 ACE2 orthologs, with further analysis showing potent ACE2-spike binding. The pseudovirus infection assays confirmed that the wild-type virus could easily infect most cell lines except for the 5 with poor ACE2-spike binding. Thus, ACE2-spike binding correlates well with infectivity in ACE2-expressing cells.

Most RBD mutants also showed comparable binding to ACE2 in cells that supported spike binding by the wild-type virus, excluding the 17 with reduced spike expression. Certain mutations conferred a significant improvement or loss of infectivity. For instance, in cells expressing mouse ACE2, the presence of K417N, E484K, and N501Y led to a steeply increased infectivity.

With the horseshoe bat ACE2, E484K was the major influencer, among other mutations like V382L, N440K, G476S, P521R, and A522S, with >3-fold increase in infectivity. Other mutations conferred improved infection rates with whale ACE2 expression.

All variants with the N501Y mutant, especially the Alpha, Beta, Gamma, and Omicron variants, showed 100-fold increased infectivity with mouse ACE2-expressing cells. Other variants with E484K but not N501Y had 10-30-times higher infectivity in these cells. Certain mutations like L452R appeared to produce a synergistic effect since they increased infectivity when present with other mutations.

The Omicron showed increased infectivity, probably due to the N440K mutation, in ferretACE2 expressing cells.

Checking for neutralizing activity, they used 9 mAbs against 48 mutants with receptor binding motif (RBM) mutations. Only one of these mAbs, the 4A8, binds the N-terminal domain (NTD) of the spike, the others interacting with the RBD.

The antibodies included human, humanized mice, and mouse mAbs, belonging to Classes 1 through 4 according to their mode of recognition of the antigen. Immune escape was considered to have occurred once the concentration required to inhibit the entry of 50% of particles (IC50) dropped by four times or more, compared to that against the wild-type spike.

The findings showed that the relative neutralizing potency was reduced up to a hundred times by the E484K mutation, including that of the Regeneron mAb REGEN10933, and the human antibody COVA2-15. Similar effects were seen with the E484A mutation, except with the latter antibody.

The N501Y mutations reduced the relative neutralizing potency with COVA2-15 by 14 times. As for K417N, it reduced the neutralizing potency of REGEN10933 by over 40 times. The mutations in aa 444-456 and aa 484-494 regions also reduced the neutralizing potency enough to facilitate immune escape from neutralizing antibodies targeting the RBD.

Neutralization by HCP

HCPs from the first wave of COVID-19 were found to have varying cross-reactivity against the variants of the virus. Mutations surrounding aa439-448 and aa484 seem to markedly impact neutralization by HCP antibodies, showing them to be two essential antigenic regions.

All three HCP antibodies completely lost neutralizing potency against Omicron, while the Beta, Gamma, and other variants containing E484K became resistant to P020.

According to the authors,

The Omicron showed the most striking resistance among all variants.”

Neutralization by vaccine sera

Vaccine-elicited antisera in mice and monkeys appeared to have similar cross-neutralizing profiles to human HCP antibody P020. The greatest escape occurred, again, with Omicron, with E484K-bearing mutants showing neutralization resistance.

The third booster shot explains why vaccine antisera seem to have higher neutralizing titers for VOC/VOI than HCP, since it increased the titer of nAbs against most variants except, notably, the Delta variant.

These data appeared to be consistent with the findings that the 3-dose mRNA vaccinations help to elicit cross-variants neutralization antibodies in humans.”

Nonetheless, nAbs against the variants with a distinct antigen profile remained several-fold lower than against the wildtype.

Prevalence associated with cross-species infectivity

Interestingly, the changes in infectivity with each single-mutation RBD variant for other animal species, relative to the wildtype, were associated with the cumulative prevalence of the variant.

The cross-species-infectivity (CSI) score, derived from relative infectivity in ferret and mouse ACE-bearing cells, correlated with the cumulative prevalences in human-derived viral sequences. Further analysis showed that the most frequent mutations in human-derived viral RBD sequences were the T478K (cumulative prevalence=59%), L452R (59%), N501Y (22%), E484K and S477N (<5% each).

The greater the infection potential across species, the higher the cumulative frequencies of the RBD mutations, showing that spillover across species may be important in maintaining the transmission of the virus in humans and animals.  

Implications

In this fascinating study, the researchers showed that the circulating variants of SARS-CoV-2 can infect cells bearing various forms of the ACE2 receptor in other species, making the virus tropic for other mammals, including aquatic.

The least readily infected were ACE2 from the ferret, horseshoe bat, mouse, tupala and brown trout, but this can be overcome, especially for the first three species and orders, by RBD mutations such as K417N, E484K, and N501Y. These are found in several variants.

Both mouse and ferret, especially, are abundant and inhabit settings in close proximity to humans, making spillover to these species a matter of high epidemiological concern. These mutations have increased mouse susceptibility to the Alpha, Beta and Gamma variants, besides Omicron, compared to the early resistance to the ancestral variant.

Mink susceptibility was demonstrated earlier, with back-and-forth infections between farmed mink and farmworkers. The Y453F mutation in mink-derived SARS-CoV-2 indicated adaptation by these animals to the virus, enhancing infectivity. The VOCs/VOIs of today are also more infective in ferrets, and perhaps also in minks, this study suggests.

The increased infection potentials of RBD mutants in animals may expand the host range of SARS-CoV-2 and possibly cause cross-species spillover.”

These mutations also appear to facilitate immune evasion in many cases, as shown by the multi-fold increase in neutralization resistance with the Omicron VOC. Even with three doses of vaccine, serum samples continued to show much lower neutralizing antibody titers against Omicron compared to other variants. Newer vaccines should take advantage of current knowledge of the antigenic profile of these new variants, using mutation patches to elicit broadly neutralizing antibodies capable of neutralizing multiple variants.

These findings highlight the antigenic drift and the possible cross-species spillover driven by viral genetic changes and will guide the prediction and surveillance of SARS-CoV-2 spike mutations.”

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Risk of Myocarditis and Pericarditis Following BNT162b2 and mRNA-1273 COVID-19 Vaccination. Image Credit: Teeradej / Shutterstock.com

Study evaluates risk estimates of myocarditis and pericarditis from mRNA-1273 and BNT162b2 vaccines

by Medical Finance
July 2, 2022
0

Several messenger ribonucleic acid (mRNA) vaccines have been developed to combat the ongoing coronavirus disease 2019 (COVID-19) pandemic, of which...

Study: Incidence and clinical phenotype of multisystem inflammatory syndrome in children after infection with the SARS-CoV-2 delta variant by vaccination status: a Danish nationwide prospective cohort study. Image Credit: NIAID

More evidence that pediatric COVID vaccination prevents MIS-C

by Medical Finance
July 2, 2022
0

Although severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causal agent of coronavirus disease 2019 (COVID-19) pandemic, does not affect children...

Study: Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Image Credit: ker_vii / Shutterstock

Remdesivir shows no significant effect on patients with COVID-19 in Solidarity trial

by Medical Finance
July 2, 2022
0

Even as the coronavirus disease 2019 (COVID-19) continues to cause thousands of new cases and dozens of deaths each day,...

Report: Global excess deaths associated with COVID-19, January 2020 - December 2021. Image Credit: VK Studio / Shutterstock

About 15 million additional deaths attributed to COVID-19 between January 2020 and December 2021

by Medical Finance
July 2, 2022
0

The World Health Organization (WHO) has released new figures showing that the coronavirus disease 2019 (COVID-19) pandemic caused almost 15...

Surveying communities may be a useful tool for predicting COVID-19 case trajectories

UK Prime Minister calls on international tourists to visit one of the most open countries in Europe

by Medical Finance
July 2, 2022
0

Prime Minister Boris Johnson today calls on international tourists to visit the UK and enjoy the sights and sounds of...

Study: Aerosol measurement identifies SARS-CoV 2 PCR positive adults compared with healthy controls. Image Credit: Aliaksandra Post/Shutterstock.com

Study compares exhaled aerosols in SARS-CoV-2 infected individuals and healthy controls

by Medical Finance
July 2, 2022
0

To date, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has claimed the lives of more than 5.6 million...

Next Post
New cryo-EM method may be able to shortcut a big step in modern vaccine development

New cryo-EM method may be able to shortcut a big step in modern vaccine development

Study: Will the COVID-19 pandemic end with the Delta and Omicron variants? Image Credit: G.Tbov/Shutterstock

Scientists explore the possibility of Omicron ending the COVID-19 pandemic

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: Vaccine Protection Against the SARS-CoV-2 Omicron Variant in Macaques. Image Credit: Fayeem/Shutterstock
    Protective efficacy of BNT162b2 and Ad26.COV2.S against SARS-CoV-2 Omicron challenge in nonhuman primates
  • Study: Experimental infection of mink with SARS-COV-2 Omicron (BA.1) variant leads to symptomatic disease with lung pathology and transmission. Image Credit: Ghost Bear/Shutterstock
    Study shows mink can be infected by Omicron and efficiently transmit the virus to other mink
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply